Phaseline

Companies › Stealth BioTherapeutics

Stealth BioTherapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 4, 1 Phase 3; Metabolic and endocrine, Ophthalmology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Elamipretide
OPA1-targeted peptide; mitochondrial function enhancer
OPA1Phase 4Barth Syndrome; Age Related Macular Degeneration (ARMD)Aug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06373731ElamipretidePhase 3Age Related Macular Degeneration (ARMD)OphthalmologyAug 2027
NCT07531251ElamipretidePhase 4Barth SyndromeMetabolic and endocrineSep 2029

From the company's SEC filings

Complete response letters from FDA

Targets

OPA1 (1)

Companies with the same targets

PYC Therapeutics

Companies built like this

Ascendis Pharma Bone Diseases BioXTek HealthTech Wound Care PolarityTE Royal Biologics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.